News & Updates

Show Multimedia Only

PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC

11 Mar 2026 by

Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.

PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC

11 Mar 2026

Physical activity before, during pregnancy boosts neurodevelopment in offspring

11 Mar 2026

Maternal physical activity before and during pregnancy appears to have favourable effects of the neurodevelopment of children, as reported in a study.

Physical activity before, during pregnancy boosts neurodevelopment in offspring

11 Mar 2026

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

11 Mar 2026 by

Cumulative angiotensin II–stimulating (vs angiotensin II–inhibiting) antihypertensive exposure is associated with lower risk of certain dementia-related neuropathologies, a US study has found.

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

11 Mar 2026

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

10 Mar 2026

Treatment with the transthyretin stabilizer tafamidis helps lower mortality and reduce hospital readmissions for acute heart failure in octogenarian patients with transthyretin cardiac amyloidosis, as shown in a study.

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

10 Mar 2026

RSV-related infant hospitalization outcomes post-nirsevimab or RSVpreF immunization: Evidence from a French cohort study

10 Mar 2026 by

Preventing respiratory syncytial virus (RSV) in infants can be achieved through maternal vaccination with the RSV prefusion F protein (RSVpreF) vaccine or administration of the monoclonal antibody nirsevimab—strategies endorsed by the WHO. In a French population-based cohort study, nirsevimab has been associated with lower risks of RSV-related hospitalizations and severe outcomes.

RSV-related infant hospitalization outcomes post-nirsevimab or RSVpreF immunization: Evidence from a French cohort study

10 Mar 2026

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

10 Mar 2026

Treatment with REP 2139-Mg (REP), a nucleic acid polymer, demonstrates efficacy and an acceptable safety profile among patients with hepatitis D virus (HDV) and advanced chronic liver disease (CLD), reports a recent study.

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

10 Mar 2026

Pig-to-human liver transplantation promises cure for hepatic diseases

10 Mar 2026 by

A genetically engineered pig liver has been successfully transplanted in a living human, according to a recent study, noting the challenge posed by postoperative xenotransplantation-associated thrombotic microangiopathy (xTMA) to long-term success.

Pig-to-human liver transplantation promises cure for hepatic diseases

10 Mar 2026

Is auto-titrating noninferior to fixed CPAP for OHS with severe OSA?

10 Mar 2026

A recent study has shown the comparable effectiveness of fixed (fCPAP) and auto-titrating continuous positive airway pressure (APAP), with some outcomes favouring fCPAP, in patients with obesity hypoventilation syndrome (OHS) and severe obstructive sleep apnoea (sOSA).

Is auto-titrating noninferior to fixed CPAP for OHS with severe OSA?

10 Mar 2026

Gait speed an early marker of covert CSVD?

10 Mar 2026 by

A cross-sectional analysis presented at ISC 2026 suggests that a decline in mobility is an earlier functional manifestation of covert cerebral small vessel disease (CSVD) than cognitive impairment.

Gait speed an early marker of covert CSVD?

10 Mar 2026

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

Treatment with the oral interleukin-1β blocker diacerein appears minimally beneficial for reducing pain in patients with knee osteoarthritis (OA), as shown in a study.

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC

PATINA: 1L palbociclib combo extends PFS in HR+, HER2+ mBC

Physical activity before, during pregnancy boosts neurodevelopment in offspring

Physical activity before, during pregnancy boosts neurodevelopment in offspring

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

RSV-related infant hospitalization outcomes post-nirsevimab or RSVpreF immunization: Evidence from a French cohort study

RSV-related infant hospitalization outcomes post-nirsevimab or RSVpreF immunization: Evidence from a French cohort study

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

Pig-to-human liver transplantation promises cure for hepatic diseases

Pig-to-human liver transplantation promises cure for hepatic diseases

Is auto-titrating noninferior to fixed CPAP for OHS with severe OSA?

Is auto-titrating noninferior to fixed CPAP for OHS with severe OSA?

Gait speed an early marker of covert CSVD?

Gait speed an early marker of covert CSVD?

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

Oral interleukin-1β blocker makes no difference in knee osteoarthritis